Articles

Gilead pursues ‘one-a-day’ HIV pill

Biopharma teams up with J&J to fight virus that causes AIDS
| 3 min read

FOSTER CITY,Calif.—California biopharmaceutical maker Gilead Sciences Inc. is teaming withJohnson & Johnson to devise a once-a-day pill for treating patientsinfected with the virus that triggers AIDS.

Gilead andJ&J's Tibotec Pharmaceuticals unit, with operations in New Jersey,announced last month they will partner in the commercial development of a pillcombining Gilead's cobicistat antiretrovirus treatment with Tibotec's proteaseinhibitor darunavir, branded as Prezista. Financial terms of the deal were notdisclosed.

Gileadspokeswoman Erin Rau explains that cobicistat is an investigationalpharmacoenhancing or "boosting" agent.

"We developedcobicistat for HIV antiretrovirals, including integrase inhibitors such aselvitegravir, and protease inhibitors such as Tibotec's darunavir," Rau says."Antiretrovirals such as these require a boosting agent in order to reach fullyeffective levels in the blood. By increasing and prolonging blood levels,boosting agents can also enable once-daily dosing."

Rau sayscobicistat essentially increases blood levels of certain HIV medicines to allowfor once-daily dosing. It is in Phase III as a standalone booster for proteaseinhibitors as well as part of Gilead's experimental "Quad" pill that combinesit with elvitegravir and Truvada.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.